Jul. 25 at 9:59 PM
$MRSN *** ATTENTION ***
$MRSN Positive clinical milestones reducing DILUTION pressure and STRONG interim or final results from ongoing Phase 1 trials (XMT-1660’s 56% response rate in adenoid cystic carcinoma) WILL boost the stock price, allowing Mersana Therapeutics (
$MRSN) to raise capital at higher valuations when needed thus = issuing fewer shares. Positive data presented at major conferences (ASCO) does also attract acquisition interest = Right Now, potentially eliminating dilution concerns entirely for the foreseeable future, ..as an option... Monday the 29th, Is the Day to call this ! ON/PM, be there.
